| 0.415 Data as of May 17 |  -0.04 / -8.79%Today’s Change | 0.40 Today|||52-Week Range 1.83 | -13.54% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $10.0M |
Talon Therapeutics, Inc. 2207 Bridgepointe Parkway San Mateo California 94404 |
| Individual stakeholders | 4.77% |
| Other institutional | 1.47% |
| Mutual fund holders | 0.76% |
| Steven R. Deitcher, MD | President, Chief Executive Officer & Director |
| Craig W. Carlson, MBA | Chief Financial Officer & Senior Vice President |
| Thomas DeZAo | Vice President-Commercial Operations & Planning |
| Nandan Oza, MBA | VP-Chemistry, Manufacturing & Controls |
| Jeffrey A. Silverman, PhD | VP-Clinical Pharmacology & Translational Research |
.
